SCHEDULE: HealthCap Reduces Carisma Therapeutics Stake
Beneficial Ownership Change
HealthCap VII, L.P. and HealthCap VII GP LLC have reduced their beneficial ownership in Carisma Therapeutics Inc. to 6.5% through a series of stock sales.
Summary
- HealthCap VII, L.P. and HealthCap VII GP LLC, as reporting persons, have amended their Schedule 13D filing regarding their beneficial ownership in Carisma Therapeutics Inc.
- Beneficial ownership now stands at 2,721,923 shares of Common Stock, representing 6.5% of the outstanding class.
- This percentage is based on approximately 41,788,096 shares of Common Stock outstanding as of August 5, 2025, as reported in Carisma Therapeutics Inc.'s Quarterly Report on Form 10-Q filed on August 7, 2024.
- Reporting persons effected multiple sales of Common Stock between August 13, 2025, and August 21, 2025.
- Total shares sold across these transactions amount to 676,025 shares.
Sentiment
Score: 3
Explanation: The filing indicates a significant reduction in beneficial ownership by a major institutional investor, HealthCap, through a series of stock sales. This action typically signals a decrease in confidence or a strategic divestment, which can be perceived negatively by the market.
Negatives
- HealthCap VII, L.P. and HealthCap VII GP LLC sold a total of 676,025 shares of Carisma Therapeutics Common Stock over several days.
- The sales occurred at prices ranging from $0.228 to $0.289 per share.
- The reduction in beneficial ownership from a significant institutional investor may signal a decrease in confidence or a strategic divestment.
Risks
- A significant institutional shareholder, HealthCap VII, L.P. and HealthCap VII GP LLC, reducing their stake may be interpreted by the market as a negative signal regarding the company's future prospects or valuation.
Stakeholder Impact
- Shareholders: The divestment by a significant institutional investor may lead to negative market sentiment and potential downward pressure on the stock price.
Key Dates
| Date | Description |
|---|---|
| August 7, 2024 | Carisma Therapeutics Inc. filed its Quarterly Report on Form 10-Q, reporting shares outstanding as of August 5, 2025. |
| August 5, 2025 | Approximate number of Common Stock shares outstanding (41,788,096) reported by the Issuer. |
| August 13, 2025 | Sold 39,100 shares of Common Stock at $0.289 per share. |
| August 14, 2025 | Sold 81,003 shares of Common Stock at $0.284 per share. |
| August 15, 2025 | Sold 50,402 shares of Common Stock at $0.284 per share. |
| August 18, 2025 | Sold 72,617 shares of Common Stock at $0.28 per share. |
| August 19, 2025 | Date of event requiring filing of this statement; sold 184,500 shares of Common Stock at $0.247 per share. |
| August 20, 2025 | Sold 134,000 shares of Common Stock at $0.228 per share. |
| August 21, 2025 | Sold 114,403 shares of Common Stock at $0.228 per share; filing date of this Schedule 13D amendment. |
Recommendation
sellThe significant reduction in stake by a major institutional investor like HealthCap, through consistent sales over several days, suggests a lack of conviction or a strategic exit. This action often precedes further price declines as it signals potential underlying issues or a shift in investor sentiment from a knowledgeable party. Investors should consider this divestment as a cautionary signal.
Keywords
Carisma Therapeutics, HealthCap, Schedule 13D, Beneficial Ownership, Stock Sales, Biotechnology, Pharmaceuticals, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.